Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Aug 05, 2021 11:03am
87 Views
Post# 33654645

RE:RE:Share price

RE:RE:Share price
porksniffer wrote:
Lookingforclues wrote: Above never went over I think $5.12  but the shares were being bought back at up to $5.24



What does it matter? They were buying back as high as $7,50 years ago and have been buying all the way down losing all the way costing shareholders tens of millions. Meir's warnings were ignored because of arrogance. It is quite hilarious to watch the market school this arrogant managment. 


They also sold those shares to the public above 7.50 years before. Then bought them back for less. That's the past though, the reality is they are buying what they believe to be undervalued shares. Time will tell who's right. 

I like what I'm seeing. I think this will be an interesting turning point in Knight. They are very slowly winding down their investments which will provide some liquidity, and they are putting cash to work in acquiring drugs and buybacks. As they start to become profitable in their main business without relying on investment returns this will get very interesting.


<< Previous
Bullboard Posts
Next >>